Natera's Q2 2026 Revenue Surges 38% on Oncology Test Growth
Event summary
- Natera reported $752.8M in Q2 2026 revenue, up 37.7% YoY from $546.6M.
- Oncology tests grew 57.2% YoY to 296,700 units, with clinical MRD oncology units increasing by 34,000 sequentially.
- Gross margin improved to 64.5%, up from 63.4% in Q2 2025.
- Net loss narrowed to $67M from $100.9M YoY.
- Raised 2026 revenue guidance by $100M at the midpoint.
The big picture
Natera's strong Q2 performance reflects the growing demand for precision oncology diagnostics, particularly as cancer detection and monitoring become more personalized. The company's ability to scale its operations while maintaining profitability will be critical as it competes in a rapidly evolving genetic testing market.
What we're watching
- Oncology Momentum
- Whether the 57% YoY growth in oncology tests can be sustained as Natera expands its clinical MRD offerings.
- Operational Efficiency
- How the company will manage rising operating expenses, up 21.5% YoY, while maintaining gross margin improvements.
- Regulatory Tailwinds
- The impact of recent regulatory approvals for Signatera and expanded Medicare coverage for Prospera on future growth.
Related topics